Document Detail

Early use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: evidence from clinical trials.
MedLine Citation:
PMID:  19032914     Owner:  NLM     Status:  MEDLINE    
Following acute myocardial infarction, patients are at increased risk of developing heart failure, which is more prevalent in those with reduced ventricular systolic function. Activation of the renin-angiotensin-aldosterone system, which occurs early after myocardial injury, plays a central role in the pathogenesis of subsequent cardiac structural and functional abnormalities. The early use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers has been tested in several large randomized clinical trials. The results of these trials show that this treatment strategy reduces the incidence of heart failure and mortality in the postmyocardial infarction patient. The magnitude of benefit is larger in patients with high-risk features, particularly those with large infarct size and the presence of heart failure or left ventricular systolic dysfunction at the time of myocardial injury. Careful use of these agents is essential in avoiding clinically significant hypotension in the critical period.
George V Moukarbel; Scott D Solomon
Related Documents :
16970134 - Is digoxin a drug of the past?
14727944 - Defining the role of calcium channel antagonists in heart failure due to systolic dysfu...
18946434 - Tricks and pitfalls regarding the hemodynamics of patients undergoing non-transplantati...
9833144 - Digitalis therapy--relevance of heart rate reduction.
23330114 - Resident cardiomyocyte precursor stem cells in the myocardium of infants of the first t...
21084124 - The development of anemia of inflammation during acute myocardial infarction.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current heart failure reports     Volume:  5     ISSN:  1546-9549     ISO Abbreviation:  Curr Heart Fail Rep     Publication Date:  2008 Dec 
Date Detail:
Created Date:  2008-11-26     Completed Date:  2009-04-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101196487     Medline TA:  Curr Heart Fail Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  197-203     Citation Subset:  IM    
Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Heart Failure / drug therapy*,  etiology*
Myocardial Infarction / complications*,  drug therapy*
Randomized Controlled Trials as Topic
Renin-Angiotensin System / drug effects*,  physiology
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Role of echocardiography in acute myocardial infarction.
Next Document:  Role of cardiac surgery in the post-myocardial infarction patient with heart failure.